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Abstract
Objective: The objective of this selective EBM review is to determine whether or not melatonin
is an effective treatment for sleep problems in Autism.
Study Design: Review of three English language, randomized controlled blinded trials published
within peer-reviewed journals from 2006-2010 evaluating the efficacy of Melatonin as an oral
sleep supplement in diagnosed autistic children.
Data Sources: A double blind, randomized, placebo-controlled, crossover trial; a randomized
controlled crossover trial; and a randomized controlled trial found using Cochrane, PubMed, and
DynaMed.
Outcomes Measured: Total night’s sleep duration, number of awakenings, and sleep latency time
were all measured using both sleep diaries, completed by the parents or caregivers, as well as
Actiwatch, a device worn to measure the activity of a participant. Common side effects of
Melatonin were measured using a Side Effects Questionnaire (SEQ).
Results: Wirojanan et al. 2008 reported night sleep duration was longer on Melatonin than
placebo by 21 minutes (p=0.02). Wright et al. 2010 reported a significant difference between
Melatonin and placebo in total sleep by an average of 52.3 minutes (p=0.002). Garstang et al.
2006 reported an increase from 8.05h to 9.84h total sleep duration.
Wirojanan et al. 2008 and Wright et al. 2010 reported no significant difference in number of
night awakenings. Garstang et al. 2006 reported a difference between 0.35 baseline to 0.08 with
Melatonin.
Wirojanan et al. 2008 reported a mean sleep-onset latency shorter by 28 minutes (p=0.0001).
Wright et al. 2010 reported an improvement of sleep latency by an average of 47 min (p=0.004).
Garstang et al. 2006 reported a difference in sleep latency from 2.6h baseline to 1.06h with use
of Melatonin. Wright et al. 2010 reported no significant side effects in the SEQ.
Conclusion: The results of the three studies presented evidence that the use of Melatonin to
improve sleep problems in children with Autism is a safe and effective treatment option. While
there is no significant improvement in the number of times a child awakens during the night,
there is statistical significance to show using Melatonin improves sleep latency and total night’s
sleep.
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Introduction
The National Institute of Neurological Disorders and Stroke defines autism by a range of
complex neurodevelopment disorders, characterized by social impairments, communication
difficulties, and restricted, repetitive, and stereotyped patterns of behavior1. There are different
types of autism that all fall within what clinicians call a spectrum, thus the term Autism
Spectrum Disorder (ASD). The spectrum ranges from classical ASD, the most severe form, to
Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).
The incidence of autism has been increasing rapidly over the past decade. The CDC’s
Autism and Developmental Disabilities Monitoring Network (ADDM) estimates about 1 in 88
children have been identified with ASD2. While there is no difference in race, ethnic, and
socioeconomic groups there is a predilection for sex. ASD is five times more common in males
(1 in 54) than in females (1 in 252)2. The cause of the rise in numbers is currently unknown and,
because the cause of autism has yet to be identified, these numbers will continue to increase.
This problem is not only a cause for concern within the general public but also within the
medical profession because there are many medical needs for a child with autism.
Sleep disturbances are reported in up to 89% of children with autism3. Some of the most
common sleep dyssomnias reported in children with autism are difficulties falling asleep,
recurrent night awakenings, and total length of time asleep. The occurrence of sleep disturbances
put children with autism at greater risk for more complex complications like further
developmental delays, behavioral difficulties, and psychological concerns3. These sleep
disturbances can cause issues not only for the child but the caretaker as well. As physician
assistants it is our duty to not only give guidance to parents with autistic children but also to
better the lives of the children themselves.

Melatonin is an inexpensive and readily available, over the counter solution for not only
autistic children with sleep disturbances but also for the general public with sleep difficulties. A
bottle of 100 3mg tablets costs $5.99 in a drug store like GNC or CVS4. This cost is far less than
any prescribed sleep aid such as Ambien CR, Lunesta, and Sonata that costs an average of $56,
$56, and $38 respectively for only seven doses5.
Autism is a multisystem condition that has to be handled by a wide range of physicians.
While a pediatrician can handle the child’s overall health and any acute problems that arise,
psychologists and speech therapists should handle issues such as cognitive delay and speech.
Physical therapists can be referred to for musculature and motor function complications. By
improving the child’s sleep you therefore improve their growth, behavior issues, and
psychological problems. It is therefore assumed that with better general overall health autistic
patients would have less frequent office visits.
There are many different hypotheses about why children with ASD have sleep
disturbances. One of the most recent theories involves the N-Acetylserotonin Omethyltransferase (ASMT) gene that is responsible for encoding the last enzyme of melatonin
synthesis. In children with ASD, this gene was shown to be significantly less active, thus
indicating lower levels of melatonin6.
Current treatment for children that have ASD with associated sleep disturbances includes
antiepileptic therapies such as carbamazepine, gabapentin, topiramate, and valproic acid;
psychological therapies including behavioral management and one-on-one therapy sessions; and
antidepressants like mirtazapine and trazodone7.
Melatonin has been used to treat insomnia associated with shift work, jet lag, and delayed
sleep for decades3. It is thought that because there has been evidence that suggests children with

ASD have a lower blood level of melatonin at night, synthetically substituting the melatonin will
improve sleep.
Objective
The objective of this selective EBM review is to determine whether or not melatonin is
an effective treatment for sleep problems in autism.
Methods
Patients in this study were between the ages of 2 and 16 years old with a diagnosed
autism spectrum disorder that have significant sleep difficulties as reported by either their
parents or physicians. One study reviewed is a double blind, randomized, placebo-controlled,
crossover trial3. Another is a randomized, controlled, crossover trial6. Finally, the third study
reviewed is a randomized controlled trial8. The intervention evaluated throughout the three trials
was giving the participant a dose of melatonin between 2 and 10 mg before bedtime. In one of
the studies the child was started on 2mg 30-40 minutes prior to bedtime and titrated every three
nights by 2 mg to a max of 10 mg until “good sleep was achieved6. Another study allowed only 3
mg of medication delivered 30 minutes prior to bedtime over a two-week trial3. Finally a study
gave participants a 5 mg dose of medication for four weeks8. The comparison to the treatment
group receiving melatonin was the experimental group who received a visually matched placebo.
The outcomes analyzed all qualified as patient oriented evidence that matters (POEMs) and
included total night’s sleep duration, number of awakenings, and sleep latency time.
The three studies reviewed were all written in English and published in peer-reviewed
journals (Journal of Autism Development Disorder, Journal of Clinical Sleep Medicine, and The
Authors Journal) in the years of 2006,2008, and 2010. The author using key words autism and
melatonin performed a detailed search using research databases such as PubMed, Cochrane, and

DynaMed. Table 1 illustrates the specific inclusion and exclusion criteria for each study.
Inclusion criteria included children between the ages of 2 and 16 years old diagnosed with ASD
by a pediatrician, psychologist, and WHO research diagnostic criteria without successful
behavior management and free of medications. Exclusion criteria included children who had
previously used melatonin as well as children currently on any sedative or psychotropic
medication. One study allowed children to participate if there was a 4-week medication free
period completed prior to the trial8. The summary of statistics reported and utilized in the studies
were confidence intervals (CI), p-values, relative risk increase (RRI), absolute risk increase
(ARI), and number needed to harm (NNH).
Table 1: Demographics & Characteristics of included studies
Study

Type

# Pts
11

Age
(yrs)
4-16

Inclusion
Criteria
- Diagnosed
with ASD by a
pediatrician or
psychologist
- Children with
learning
disabilities,
ADHD, and
dyspraxia

Garstang
(2006)

Randomized
placebocontrolled
double blind
trial

Wright
(2010)

Double blind
randomized
controlled
crossover
trial

20

3-16

-Children with
ASD who had
been referred
because of
serious sleep
problems
-ASD
diagnosed
based on WHO
research
diagnostic
criteria
-Non successful

Exclusion
Criteria
-Children that
had used
melatonin
previously
-Children
who had been
using other
sedative
medication
not allowed
trial entry
until they had
completed 4
weeks of
medication
-Children
previously or
currently on
melatonin
-On
psychotropic
medication
-Those
suffering
from related
disorders like
Fragile X or
Rett’s

W/D

Interventions

4

Regime of
5mg of
melatonin

3

Started on
2mg
melatonin
30-40
minutes
before
bedtime and
increased
2mg every
three nights
to max dose
of 10mg

Wirojanan
(2008)

Randomized
double blind,
placebocontrolled,
crossover
trial

18

2-15.3

behavior
management
-ASD was
diagnosed by a
team of
developmental
pediatricians
and
psychologists
-Free from
medications

None

6

Regimen of
melatonin
3mg, 30
minutes
before
bedtime.

Outcomes Measured
The outcomes measured in the reviewed studies are all Patient Oriented Evidence that
Matters (POEMs). Wirojanan et al3 measured participants after a 1 week baseline period,
children were then instructed to take a 2 week medication consisting of either placebo or
melatonin 30 minutes prior to bedtime. Total night sleep duration, sleep-onset latency (the time
from bedtime to sleep onset time), and number of night awakenings were recorded using a sleep
diary, completed by the parent or guardian, and Actiwatch3. Actiwatch is a wrist-worn device
that measures the activity counts each minute. A count of 100 or above for 2 consecutive minutes
was considered the beginning of an awakening3. Differences between the melatonin group and
placebo group were compared and analyzed via p-values. Wright et al6 measured a baseline for
two groups for 1 month. Sleep diaries were kept by the parent or guardian and collected by the
researcher every month for 9 months. These sleep diaries recorded sleep latency (time from
starting bedtime routine to sleep), total sleep time, and number of awakenings. These values
were again analyzed via p-values. A Side Effects Questionnaire (SEQ) was also kept by the
parents recording all literature and manufacturer reported side effects for melatonin, theoretical
side effects, common generic side effects and any other noted changes in health and wellbeing6.
These results were analyzed and reported using p-value. Garstang et al8 measured a baseline

assessment for 1 week before the medication was distributed. Once the medication was
distributed a 4 week monitoring period went on where the parents used a sleep chart to record the
total sleep time, sleep latency, and number of awakenings. This data was then analyzed using
95% confidence intervals for the baseline period, placebo period, and melatonin period.
Results
In the study performed by Wirojanan et al,3 18 patients (16 boys, 2 girls) ages 2 to 15.3
years old were recruited through the Medical Investigation of Neurodevelopmental Disorders
(M.I.N.D) Institute clinic at the University of California, Davis. The participants were given a
number based on the order they were enrolled in the study. The document identifying the patient
to their number was locked in the investigator’s file until the study concluded3. Patients
conducted a 1-week baseline period and then randomized into treatment and placebo groups. The
participants were told to administer 3mg oral medication 30 minutes prior to bedtime3. For all
three studies, statistical analysis was done on the intent to treat (ITT) population. This study only
included continuous data that could not be converted into dichotomous data.
Six participants were not included in the final results of the study. Three of the six were
excluded because their caregiver failed to complete the sleep diaries. Another was excluded
because their Actiwatch was not worn during the treatment block. One of the subjects was
excluded because their Actiwatch was not worn during the intervention block. Finally, one other
was excluded because the family did not follow the studies protocol3.
The total night’s sleep, sleep latency time, and number of night awakenings were
recorded using both actigraph and a daily sleep diary. Actiwatch data consisted of activity counts
for each 1-minute epoch3. This data was extracted from the watch and analyzed with ActiWare
software. The criteria for a child to be considered awake was an activity count of 100 or above

for two consecutive minutes3. All participants’ data was used in a complete case analysis (CC),
in which only cases that completed all observations were included3. Parametric t-test was also
used to compare the averages of all participants3. P-value was recorded and determined to be
significant for both night sleep duration and sleep-latency time (see table 2)3. While number of
night awakenings did not demonstrate a significant p-value table 3 demonstrates there was a
decrease while on melatonin.
Table 2: Nonparametric Analysis of the Sleep Variables for the CC Data Set
Sle e p variable s

Data se t

p Value

Night sleep duration

CC

0.0019

Sleep-latency time

CC

0.0001

Number of night awakenings

CC

0.93

Table 3: Comparison of Sleep Variables During Placebo and Melatonin
Variable s
Total night sle e p
duration, h:min
Sle e p-late ncy time ,
min:s
Awake nings,
no./night

Place bo

Me latonin

p Value

7:54 (1:07)

8:15 (1:15)

0.057

53:35 (60:33)

25:30 (16:53)

0.10

2.07 (1.5)

1.99 (1.2)

0.73

In the study performed by Wright et al6, 20 children (16 male, 4 female) ranging from
ages 4 to 16 years old were selected to participate in the study6. They were selected after being
referred for serious sleep problems by their pediatrician or specialist CAMHS (child and
adolescent mental health services). Children excluded were those previously or currently on
melatonin, those currently on psychotropic medication, and those suffering from related
developmental or neurological disorder, such as Fragile X or Rett syndrome6. Children also had
to have had previous behavior management that had failed to be included.
Seventeen patients completed the study and were included in the final data6. One
participant dropped out because it was too difficult to give medication, one because the guardian

did not complete the diary, one because of significant benefits, and one because of apparent
ineffectiveness of the medication6. These seventeen were randomized into treatment and placebo
groups. A sleep diary was kept in order to record data for total sleep, sleep latency, and number
of awakenings6. A side effects questionnaire (SEQ) to measure all literature and manufacturer
reported side effects for melatonin, theoretical side effects, common generic side effects and any
other noted changes in health or wellbeing was taken at the start of the study, end of the study,
and after every 3 month period6.
After randomizing the 2 groups, everyone was monitored for 1 month to get a baseline.
Then patients were placed on either placebo or melatonin for 3 months. Everyone started on 2
mg 30-40 minutes before bedtime6. The parents increased the dose every three nights by 2mg
maxing out at 10 mg6. If guardian noticed “good sleep” the child was stabilized at that current
dosage6. For data in the SEQ, baseline scores were compared using Mann-Whitney U- Test6. For
melatonin and placebo score comparison a Wilcoxon Signed Ranks Test was used6. All analyses
were performed on SPSS and a p-value of <0.05 was considered to indicate statistical
significance6. There was statistical significance in sleep latency and total sleep (table 4).
However, there was no significance in number of night awakenings. Also, there was no
significance reported for the SEQ. Stating all reported side effects had a p-value of greater than
0.056. Specifically daytime drowsiness had a CER of 68.8% from the placebo and EER of 35.3%
from the melatonin. The RRI was determined to be -48.7%. The ARI was calculated at -33.5%
and the NNH were determined to be -2.9 (or 3 patients) see table 5.
Table 4: Mean scores on sleep diary, general health questionnaire, and sleep difficulties
questionnaire for baseline, melatonin and placebo arms of the trial
Sle e p diary

Base line

Sle e p late ncy 135.0 (63.0)
(min)

Me latonin

Place bo

Me an
diffe re nce

Te st statistic

82.84 (50.61)

124.79

46.7 (55)

t(15)=3.394, p=
0.004

No. of
awake nings

0.5 (0.5)

0.43 (0.64)

0.58 (0.74)

0.1 (0.4)

t(15)=1.313, p=
0.209

Total sle e p
[min]

499.9 (66.4)

556.11 (53.59)

507.66 (70.67)

52.3 (55.1)

t=3.75, p= 0.002

Relative risk
increase (RRI)

Absolute risk
increase (ARI)

Number needed to
harm (NNH)

EER- CER
CER
35.3 – 68.8
68.8

EER – CER

1/ARI

35.3 – 68.8

1/-33.5

- 48.7%

- 33.5%

- 3 (3 patients)

Table 5: SEQ Calculations
YOUR CALCULATIONS for Harm –
using dichotomous data
Daytime Drowsiness
CER
EER
Placebo

Melatonin

68.8%

35.3%

In the study performed by Garstang et al8, 11 children (7 male, 4 female) ranging from
ages 4 to 16 years old were selected to participate by recruitment from community pediatricians,
special schools, local autism-support service and local parent-support groups8. Children who had
used melatonin previously were excluded8. While children who had been using other sedative
medication had to complete a 4-week medication free trial before allowed entry.
Seven children completed the study. The trial had to be suspended because of the placebo
pill being empty. This suspension forced two girls to drop out8. One boy dropped out because of
a housing relocation and one girl became involved in a child protection enquiry8.
Children were randomized into either the treatment or placebo group at the beginning of
the study. A sleep diary taken by the guardian was used to measure total sleep, wakings per night
and sleep latency. Their guardians were told to keep a 1-week sleep diary prior to the study
beginning in order to establish a baseline8. The participants were then given 5mg of either
melatonin or a look-a-like placebo and told to take orally before bedtime8. The guardians were
advised to keep a sleep diary recording total sleep time, sleep latency and night awakenings for 4
weeks. A 1-week washout was performed and then another 4-week trial was started8. The mean

and 95% Confidence interval (CI) were calculated and reported (see table 6). The study reported
that all children completing the study remained on melatonin and that 75% of patients that
dropped out were eventually prescribed melatonin8.
Table 6: Mean and 95% confidence intervals (CI) of treatment on sleep patterns
Sle e p late ncy (h)

W akings pe r night

Total sle e p (h)

Me an

95% C I

Me an

95% C I

Me an

95% C I

Base line

2.60

2.28-2.93

0.35

0.18-0.53

8.05

7.65-8.44

Place bo

1.91

1.78-2.03

0.26

0.20-0.34

8.75

8.56-8.98

Me latonin

1.06

0.98-1.13

0.08

0.04-0.12

9.84

9.68-9.99

Discussion
This systematic review investigated three studies to determine whether or not the use of
melatonin in children with ASD was a viable option to treat and improve sleep patterns. All three
studies demonstrated that the use of melatonin significantly improved total night sleep and sleep
latency times when compared to the placebo.
While all three studies used different dosages of melatonin it is undetermined as to
whether or not melatonin is a better treatment option when compared to other current
pharmacological treatments like antiepileptic therapies or antidepressants. Wirojanan et al.
conclude that the use of melatonin in combination with behavior therapies and proper sleep
hygiene practices should be used for best effective results3.
Among the studies included in this selective review, there were several limitations
expressed by each study. In both Wright et al. and Wirojanan et al. studies, the suggestion that
bioavailability and metabolism may play a role into the effectiveness of being treated with a set
dosage of melatonin was discussed. Wirojanan et al stating, “some participants may have needed
higher dose for obtaining a significant response, whereas other might have benefited from lower
dose.”3 While Wright et al. used a dosing range of 2mg to 10 mg and stating, “some children

may require larger doses than those being suggested in literature, and that there may be
considerable variability in dose needed.”6. Additionally, both Wright et al. and Garstang et al.
reported small sample sizes and difficulty with recruiting. Garstang et al. suggested that in future
studies a multi-centre approach should be used because many of the participants were excluded
because melatonin was already being used in their child with ASD.
Conclusion
Based on the information provided in these three studies, it has been concluded that
Melatonin is an effective treatment for children that struggle with sleep problems compared to
placebo at doses of 2mg to 10 mg. However, there are several issues with these studies that
would require further examination. One main concern is the amount of children enrolled in all
three studies. All three consisted of small numbers of participants, which can skew what a full
spectrum view of the average population with ASD would look like. Another issue is
bioavailability. One study allowed participants a dose range of 2mg to 10 mg while the other two
studies only allowed a 3mg dose and 5mg dose. Due to the different severity types of ASD it is
not known whether children with a more severe form of ASD require a larger dose of melatonin
versus the children with a less severe form of ASD.
Future studies in this area of concern should be conducted to discuss the exact dosage of
melatonin needed to increase outcomes of better sleep. These studies would have to be longer in
length due to different groups testing different dosages of melatonin. Also instead of a wristband
to measure sleep activity a camera could be installed in the child’s room to visually record the
number of night awakenings. Neurologists and Pulmonologists should also be consulted to
further classify when a participant is termed “awake” versus other psychological abnormalities.
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